Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Expert advisers including neurologists and patient representatives have expressed concern at the European Commission’s (EC) decision to formally approve the Alzheimer’s drug lecanemab (Leqembi) ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

The voices, values and lived experience of people living with dementia - and their families - must shape the path forward for ...